Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Details

Ressource 1Download: serval:BIB_7FF3875D6472.P001 (468.26 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_7FF3875D6472
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
Journal
Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
Author(s)
Konstantinidis L., Mantel I., Pournaras J.A., Zografos L., Ambresin A.
ISSN
1435-702X[electronic]
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
247
Number
3
Pages
311-318
Language
english
Abstract
BACKGROUND: Macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to severe vision loss. The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV. METHODS: We conducted a prospective, consecutive, interventional study of patients with subfoveal or juxtafoveal CNV secondary to pathologic myopia (PM) treated with intravitreal injection of ranibizumab in the Jules Gonin University Eye Hospital from June 2006 to February 2008. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and fluorescein angiography (FA) were performed at baseline and monthly for all patients. Indications for retreatment were loss in BCVA associated either with persistent leakage from CNV shown on FA, and/or evidence of CNV activity on OCT. RESULTS: The study included 14 eyes of 14 patients. The mean spherical equivalent refractive error was -12.5 (range, -8.0 D to -16.0 D). Mean time of follow-up was 8.4 months (range from 3 to 16 months, SD: 3). The mean number of intravitreal injections administered for each patient was 2.36 (SD 1.5). The mean initial visual acuity (VA) was 0.19 decimal equivalent (log-MAR: 0.71, SD: 0.3). A statistically significant improvement to a mean VA of 0.48 decimal equivalent (log-MAR:0.32, SD: 0.25) was demonstrated at the final follow-up. VA improved by a mean of 3.86 (SD 2.74) lines. Nine patients (64%) demonstrated a gain of 3 or more lines. Mean central macular thickness (CMT) measured with OCT was 304 microm (SD: 39) at the baseline, and was reduced significantly at the final follow-up to 153 microm (SD: 23). Average CMT reduction was 170 microm (SD: 57). No injection complications or drug-related side effects were noted during the follow-up period. CONCLUSIONS: In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvements.
Keywords
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Choroidal Neovascularization, Female, Fluorescein Angiography, Humans, Injections, Male, Middle Aged, Myopia, Degenerative, Prospective Studies, Tomography, Optical Coherence, Visual Acuity, Vitreous Body
Pubmed
Web of science
Open Access
Yes
Create date
17/04/2009 19:27
Last modification date
01/10/2019 7:18
Usage data